sxyl[Table_Main] 公司研究|医疗保健|医疗保健设备与服务 证券研究报告 [Table_TargetPrice] 三鑫医疗(300453)公司点评报告 2024 年 10 月 17 日 [Table_Title] 业绩增长符合预期，产业项目有序扩张 ——三鑫医疗（300453.SZ）2024 三季报点评 [Table_Summary] 事件： 公司发布 2024 三季度报告，2024 年 Q1-3 实现营业收入 10.82 亿元，同比 增长 16.38%；归母净利润 1.68 亿元，同比增长 18.74%；扣非归母净利润 1.52 亿元，同比增长 18.84%，EPS 为 0.32 元。 主营业务增长稳健，盈利能力持续提升 公司前三季度业绩符合预期，其中 2024Q3 公司实现收入 3.96 亿元，同比 增长 13.69%；归母净利润 0.62 亿元，同比增长 18.75%；扣非后归母净利 润 0.57 亿元，同比增长 16.29%，单季度业绩继续维持稳健增长。2024Q1- 3 公司经营效率持续提升，期间费用率小幅下降，其中毛利率 35.03% （+0.63pct），净利率 16.94%（+0 ...

三鑫医疗（ [Table_StockNameRptType] 300453） 公司点评 业绩增长稳健，盈利能力持续提升 1/24 4/24 7/24 三鑫医疗 沪深300 公司价格与沪深 300 走势比较 10/23 -41% -23% -6% 12% 30% 年三季报，前三季度公司实现营业收入 10.82 亿元 ），归母净利润为 1.68 亿元（yoy+18.74%），扣非净利润 3.96 亿元（yoy+13.69%），归母净利润 6166.70 ），扣非净利润 5717.66 万元（yoy+16.29%）。 2024年前三季度，公司研发费用为 4473.31 万元（yoy+30.80%），研发 投入持续加大。2024 年 10 月公司产品血液透析浓缩液获得医疗器械注 册证，公司血液透析产品链进一步丰富。 2024Q3，公司毛利率为 34.92%，同比降低 0.81pct，基本保持稳定；净 利率为 17.17%，同比提升 1.25pct，公司盈利能力进一步增强。 | --- | --- | |---------------------------------|------------------------ ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2024-090 江西三鑫医疗科技股份有限公司 2024年第三季度报告披露的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示：江西三鑫医疗科技股份有限公司（以下简称"公司"）《2024 年第三季度报告》于 2024 年 10 月 15 日在中国证监会指定的创业板信息披露网 站上披露，请投资者注意查阅。 2024 年 10 月 14 日，公司召开了第五届董事会第十六次会议、第五届监事 会第十五次会议，审议通过了《关于公司<2024 年第三季度报告>的议案》。 为使投资者全面了解本公司的财务状况、经营成果等，公司《2024 年第三 季度报告》于 2024 年 10 月 15 日在中国证监会指定的创业板信息披露网站巨潮 资讯网（http://www.cninfo.com.cn）披露，敬请广大投资者查阅。 特此公告 江西三鑫医疗科技股份有限公司董事会 2024 年 10 月 15 日 ...

Revenue and Profit Growth - Revenue for the third quarter reached 395.87 million yuan, a year-on-year increase of 13.69%[1] - Net profit attributable to shareholders of the listed company was 61.67 million yuan, up 18.75% year-on-year[1] - Total operating income for the current period reached 1,082,325,012.30 yuan, an increase from 929,961,012.41 yuan in the previous period[15] - Net profit attributable to the parent company's shareholders was 167,914,693.97 yuan, up from 141,410,327.37 yuan in the previous period[16] - Sales revenue from goods and services provided reached 1,166,340,242.83 yuan, up from 1,004,748,423.15 yuan in the previous period[18] - Total comprehensive income for the current period was 183,343,938.37 yuan, compared to 152,007,133.72 yuan in the previous period[16] Cash Flow and Financial Activities - Operating cash flow for the first nine months of 2024 was 323.59 million yuan, a significant increase of 54.36% compared to the same period last year[1] - Operating cash flow increased to 323.59 million yuan, up 54.3% year-over-year from 209.63 million yuan[19] - Net cash flow from investment activities was -224.91 million yuan, an improvement from -292.85 million yuan in the same period last year[19] - Net cash flow from financing activities was -186.20 million yuan, compared to -30.26 million yuan in the previous year[20] - Total cash and cash equivalents at the end of the period decreased to 111.44 million yuan from 172.12 million yuan at the beginning of the period[20] - Cash received from tax refunds was 11.48 million yuan, a significant increase from 3.04 million yuan in the previous year[19] - Cash paid for goods and services increased to 577.19 million yuan, up 20% from 480.83 million yuan[19] - Cash paid to employees and for employee benefits rose to 188.67 million yuan, up 7.7% from 175.14 million yuan[19] - Cash received from investments was 152.24 million yuan, up 19.4% from 127.50 million yuan[19] - Cash paid for dividends, profits, and interest payments surged to 156.74 million yuan, up 118.5% from 71.72 million yuan[20] Assets and Liabilities - The company's total assets grew by 6.27% to 2.16 billion yuan as of the end of the reporting period[1] - Total assets increased to 2,158,082,604.85 yuan, up from 2,030,807,833.80 yuan at the beginning of the period[11][12] - Current assets totaled 735,150,455.54 yuan, compared to 691,760,101.72 yuan at the beginning of the period[11] - Non-current assets amounted to 1,422,932,149.31 yuan, up from 1,339,047,732.08 yuan at the beginning of the period[12] - Monetary funds decreased to 121,823,246.72 yuan from 221,286,623.55 yuan at the beginning of the period[11] - Trading financial assets increased to 282,300,085.60 yuan from 141,569,185.43 yuan at the beginning of the period[11] - Accounts receivable rose to 94,250,483.68 yuan from 86,638,303.72 yuan at the beginning of the period[11] - Inventory increased to 205,486,028.98 yuan from 199,382,114.37 yuan at the beginning of the period[11] - Fixed assets grew to 823,954,846.07 yuan from 674,465,761.36 yuan at the beginning of the period[12] - Construction in progress increased to 240,396,738.19 yuan from 234,670,989.48 yuan at the beginning of the period[12] - Short-term borrowings decreased to 80,026,333.33 yuan from 120,084,513.89 yuan at the beginning of the period[12] - Total liabilities increased to 829,855,813.55 yuan from 696,843,705.65 yuan in the previous period[13] - Long-term borrowing significantly increased to 197,795,773.94 yuan from 80,376,000.00 yuan in the previous period[13] - Total owner's equity slightly decreased to 1,328,226,791.30 yuan from 1,333,964,128.15 yuan in the previous period[14] Research and Development - R&D expenses increased by 30.80% to 44.73 million yuan, driven by higher project-related expenses[4] - Research and development expenses increased to 44,733,074.43 yuan from 34,200,080.78 yuan in the previous period[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,892[6] - The top shareholder, Peng Yixing, holds a 24.70% stake in the company[6] - Minority shareholders' comprehensive income increased to 15,429,244.40 yuan from 10,596,806.35 yuan in the previous period[17] Earnings Per Share - Basic earnings per share (EPS) for the current period was 0.3232, compared to 0.2737 in the previous period[17] Financial Expenses - Financial expenses decreased by 74.06% to -499,228.59 yuan, mainly due to reduced interest income from fixed deposits[4] Long-term Loans and Investments - Long-term loans surged by 146.09% to 197.80 million yuan, primarily due to the construction of a new R&D and production base[5] - The company's investment in financial assets increased by 99.41% to 282.30 million yuan, reflecting higher purchases of wealth management products[5] Miscellaneous - The company's third-quarter report was unaudited[20]

证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | --- | |-------------------------|------------------------------------------------------|--------------------------------------------|-----------------------------------------|---------------|----------------------------------------------------------|----------------------------------------------------------------| | \n投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 | \n | 分析师会议 \n 业绩说明会 \n 路演活动 \n | 其他 电话会议 | 编号： | 20240912 ...

[Table_TargetPrice] [Table_Main] 公司研究|医疗保健|医疗保健设备与服务 证券研究报告 三鑫医疗(300453)公司点评报告 2024 年 08 月 14 日 [Table_Title] 主营血透业务稳健增长，集采落地夯实领 [Table_Invest]买入|维持 先地位 ——三鑫医疗（300453.SZ）2024 半年报点评 [Table_Summary] 事件： 公司发布 2024 半年度报告，2024 年 H1 实现营业收入 6.86 亿元，同比增 长 18.00%；归母净利润 1.06 亿元，同比增长 18.74%；扣非归母净利润 0.94 亿元，同比增长 20.44%，EPS 为 0.20 元。 主营血透业务增长稳健，两大联盟集采落地夯实公司优势地位 公司业绩符合预期，经营效率小幅提升，毛利率 35.09%（+1.49pct），净利 率 16.81%（+0.21pct）；销售费用率为 6.26%（+0.64pct），管理费用率为 6.73%（-0.68pct），研发费用率为 4.12%（+0.92pct），财务费用率为-0.07% （+0.37pct）。公司 2024 ...

证 券 研 告 公 司 研 究 究 报 2024 年 08 月 13 日 | --- | --- | --- | |------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证 券 研 告 公 司 研 究 究 报 2024 年 08 月 13 日 | --- | --- | --- | |------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

三鑫医疗（ [Table_StockNameRptType] 300453） 公司点评 2024 年中报业绩符合预期，集采+出海助力公司长久发展 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------------------------------------------------------|-------|----------|-------|-----------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

三鑫医疗（ [Table_StockNameRptType] 300453） 公司点评 2024 年中报业绩符合预期，集采+出海助力公司长久发展 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------------------------------------------------------|-------|----------|-------|-----------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...